Post-trial follow-up | Fluorouracil and dose-dense adjuvant chemotherapy in patients with early-stage breast cancer.

Fluorouracil and dose-dense adjuvant chemotherapy in patients with early-stage breast cancer (GIM2): end-of-study results from a randomised, phase 3 trial – The Lancet Oncology (link to abstract – $ for full-text)

Commentary: Dose-Dense Adjuvant Chemotherapy “Optimal” for High-Risk Early Breast Cancer – Cancer Therapy Advisor

Original Study: Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 × 2 factorial, randomised phase 3 trial – The Lancet

Commentary on Twitter

Online first: end-of-study results from the randomised, phase 3 GIM2 trial: #fluorouracil and dose-dense adjuvant #chemotherapy in patients with #early-stage #breastcancer https://t.co/9YD5w9aLY2 pic.twitter.com/RmPdi37sQB

— The Lancet Oncology (@TheLancetOncol) November 10, 2022